Antibodies to the pcrv antigen of pseudomonas aeruginosa
AssigneeKaloBios Pharmaceuticals, Inc.
InventorsChristopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
Life of this patent
Estimating the term…
Abstract
The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
Claims20
An isolated anti-PcrV antibody that selectively binds PcrV, wherein the antibody comprises a VL region that has a CDR3 having a sequence Q(Q/H)FWGTPYT (SEQ ID NO:41) and a VH region that has a CDR3 having a sequence NRGDIYYDFTYA(M/F)DX1 (SEQ ID NO:42), wherein X1 is I, Q, Y, or S.
An isolated anti-PcrV antibody that selectively binds PcrV, wherein the antibody comprises:
- a VH region having a CDR3 having a sequence NRGDIYYDFTYAMDI (SEQ ID NO:99), a CDR2 sequence VISYDGSEKWYADSVKG (SEQ ID NO:57), and a CDR1 sequence NYPMH (SEQ ID NO:54);
- and
- a VL region.
An isolated anti-PcrV antibody that selectively binds PcrV, wherein the antibody comprises:
- a VL region that comprises a CDR3 having a sequence QHFWGTPYT (SEQ ID NO:110), a CDR2 sequence DASTLQS (SEQ ID NO:73), and a CDR1 sequence RASEGVDRWLA (SEQ ID NO:69);
- and
- a VH region.
Dependencies are inferred from the claim text.